[
  {
    "ts": null,
    "headline": "What TrumpRx Means For Controversial Plan To Lower U.S. Drug Prices",
    "summary": "The White House unveiled TrumpRX as a key part of the administration's plan to lower U.S. drug prices. But serious questions remain.",
    "url": "https://finnhub.io/api/news?id=93ac76ddd429a06740265adee35ea6d9b3e54d0928f18a545bba2f355d2568ed",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759269170,
      "headline": "What TrumpRx Means For Controversial Plan To Lower U.S. Drug Prices",
      "id": 136943997,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The White House unveiled TrumpRX as a key part of the administration's plan to lower U.S. drug prices. But serious questions remain.",
      "url": "https://finnhub.io/api/news?id=93ac76ddd429a06740265adee35ea6d9b3e54d0928f18a545bba2f355d2568ed"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY) Halts Experimental Study of Muscle-Sparing Obesity Drug",
    "summary": "Eli Lilly and Company (NYSE:LLY) is among the 10 Best Money Making Stocks to Invest In. According to a U.S. registry of clinical trials, the firm has halted an experimental drug study designed to stop obesity patients from excessive muscle loss due to undisclosed strategic business reasons. The company was testing Bimagrumab, alone or in […]",
    "url": "https://finnhub.io/api/news?id=dd388188deb9228a4d5f2350e06b3feaf8a2c6c6a72cbcb5849e3a2dfe9c317d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759266928,
      "headline": "Eli Lilly and Company (LLY) Halts Experimental Study of Muscle-Sparing Obesity Drug",
      "id": 136943998,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is among the 10 Best Money Making Stocks to Invest In. According to a U.S. registry of clinical trials, the firm has halted an experimental drug study designed to stop obesity patients from excessive muscle loss due to undisclosed strategic business reasons. The company was testing Bimagrumab, alone or in […]",
      "url": "https://finnhub.io/api/news?id=dd388188deb9228a4d5f2350e06b3feaf8a2c6c6a72cbcb5849e3a2dfe9c317d"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Stock Surges After Company Makes a Deal With President Trump",
    "summary": "Pfizer shares jumped 6.83% Tuesday after President Trump said the drugmaker would offer some of its drugs on a new direct-to-consumer website and would introduce new drugs to the U.S. market at reduced prices.",
    "url": "https://finnhub.io/api/news?id=7d92d7b7741021982a383fc4de2cc1217781dc0f90208cc0b66ef8179cf823cb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759266883,
      "headline": "Pfizer Stock Surges After Company Makes a Deal With President Trump",
      "id": 136943999,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pfizer shares jumped 6.83% Tuesday after President Trump said the drugmaker would offer some of its drugs on a new direct-to-consumer website and would introduce new drugs to the U.S. market at reduced prices.",
      "url": "https://finnhub.io/api/news?id=7d92d7b7741021982a383fc4de2cc1217781dc0f90208cc0b66ef8179cf823cb"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY) Opens a New Lilly Gateway Labs Innovation Hub in San Diego",
    "summary": "With a strong profitability outlook, Eli Lilly and Company (NYSE:LLY) secures a spot on our list of the 14 Stocks That Will Double in the Next 5 Years. On September 26, 2025, Eli Lilly and Company (NYSE:LLY) opened a new Lilly Gateway Labs innovation hub in San Diego, expanding its global network of facilities supporting early-stage biotech […]",
    "url": "https://finnhub.io/api/news?id=c104d09a0cbad7de88af324f55b5af79697a3490a62e223fe96e7cecb1af314f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759265294,
      "headline": "Eli Lilly and Company (LLY) Opens a New Lilly Gateway Labs Innovation Hub in San Diego",
      "id": 136944000,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "With a strong profitability outlook, Eli Lilly and Company (NYSE:LLY) secures a spot on our list of the 14 Stocks That Will Double in the Next 5 Years. On September 26, 2025, Eli Lilly and Company (NYSE:LLY) opened a new Lilly Gateway Labs innovation hub in San Diego, expanding its global network of facilities supporting early-stage biotech […]",
      "url": "https://finnhub.io/api/news?id=c104d09a0cbad7de88af324f55b5af79697a3490a62e223fe96e7cecb1af314f"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Stock Soars on Trump’s New Drug Pricing Plan. Here’s Why.",
    "summary": "The president announced a federal government website that allows Pfizer to sell medicines at low prices to cash-paying consumers.",
    "url": "https://finnhub.io/api/news?id=04fbe0d5e9ce27db4ee3192e9532cb87df0019d8869b7be49ff119c8cd315884",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759265220,
      "headline": "Pfizer Stock Soars on Trump’s New Drug Pricing Plan. Here’s Why.",
      "id": 136944001,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The president announced a federal government website that allows Pfizer to sell medicines at low prices to cash-paying consumers.",
      "url": "https://finnhub.io/api/news?id=04fbe0d5e9ce27db4ee3192e9532cb87df0019d8869b7be49ff119c8cd315884"
    }
  },
  {
    "ts": null,
    "headline": "Stocks Settle Higher as Drug Makers and Chip Stocks Rally",
    "summary": "The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed up +0.41%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.18%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.28%. December E-mini S&P futures (ESZ25 ) rose +0.39%, and December E-mini Nasdaq futures...",
    "url": "https://finnhub.io/api/news?id=560977de8624e5089c6fe6754ae58fb8bd8bbacedc1ea7c977bd3b14a2862e71",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759264879,
      "headline": "Stocks Settle Higher as Drug Makers and Chip Stocks Rally",
      "id": 136944002,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed up +0.41%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.18%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.28%. December E-mini S&P futures (ESZ25 ) rose +0.39%, and December E-mini Nasdaq futures...",
      "url": "https://finnhub.io/api/news?id=560977de8624e5089c6fe6754ae58fb8bd8bbacedc1ea7c977bd3b14a2862e71"
    }
  },
  {
    "ts": null,
    "headline": "Stocks Post Late Rally After Trump Strikes Deal With Pfizer",
    "summary": "Gains in pharmaceutical stocks lifted indexes, despite the threat of an imminent government shutdown.",
    "url": "https://finnhub.io/api/news?id=58165ca615c2838efee6978fd1fdad750dc17a02d72693011af8e05ce8466ab1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759264680,
      "headline": "Stocks Post Late Rally After Trump Strikes Deal With Pfizer",
      "id": 136944003,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Gains in pharmaceutical stocks lifted indexes, despite the threat of an imminent government shutdown.",
      "url": "https://finnhub.io/api/news?id=58165ca615c2838efee6978fd1fdad750dc17a02d72693011af8e05ce8466ab1"
    }
  },
  {
    "ts": null,
    "headline": "Why Are Eli Lilly (LLY) Shares Soaring Today",
    "summary": "Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 5.5% in the afternoon session after reports revealed a potential drug-pricing agreement between the White House and the pharmaceutical industry.",
    "url": "https://finnhub.io/api/news?id=e64d1762f2bf933cdcbb8f60961a4a7684b8b8c0fc1c598f638dd5d9c6bf3c88",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759262744,
      "headline": "Why Are Eli Lilly (LLY) Shares Soaring Today",
      "id": 136944004,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 5.5% in the afternoon session after reports revealed a potential drug-pricing agreement between the White House and the pharmaceutical industry.",
      "url": "https://finnhub.io/api/news?id=e64d1762f2bf933cdcbb8f60961a4a7684b8b8c0fc1c598f638dd5d9c6bf3c88"
    }
  },
  {
    "ts": null,
    "headline": "Trump's Plan To Lower U.S. Drug Prices Faces Big Test",
    "summary": "But Trump might get less than he bargained for as drugmakers focus on prices abroad, rather than stateside efforts.",
    "url": "https://finnhub.io/api/news?id=456cd7f18059a60e00155564da4afeaff3d33c28c548a0a16c1e0af0e445e3eb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759250909,
      "headline": "Trump's Plan To Lower U.S. Drug Prices Faces Big Test",
      "id": 136937584,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "But Trump might get less than he bargained for as drugmakers focus on prices abroad, rather than stateside efforts.",
      "url": "https://finnhub.io/api/news?id=456cd7f18059a60e00155564da4afeaff3d33c28c548a0a16c1e0af0e445e3eb"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron: Growth Catalysts Incoming",
    "summary": "Regeneron Pharmaceuticals is seeing revenue growth in key products that is now offsetting declining revenue in its previous blockbuster drug. Read why REGN is a Buy.",
    "url": "https://finnhub.io/api/news?id=bb66c6e3504758db315ceacc9eb99a4641b7f297c884b7e7544ade750efc5d34",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759249535,
      "headline": "Regeneron: Growth Catalysts Incoming",
      "id": 136939389,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1386962383/image_1386962383.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Regeneron Pharmaceuticals is seeing revenue growth in key products that is now offsetting declining revenue in its previous blockbuster drug. Read why REGN is a Buy.",
      "url": "https://finnhub.io/api/news?id=bb66c6e3504758db315ceacc9eb99a4641b7f297c884b7e7544ade750efc5d34"
    }
  },
  {
    "ts": null,
    "headline": "Metsera Posts Promising Weight-Loss Drug Results. It Could Be a Win for Pfizer.",
    "summary": "Pfizer said last week it would pay $47.50 per share for Metsera, and an extra $22.50 per share if its drugs hit certain milestones.",
    "url": "https://finnhub.io/api/news?id=042b8dcc6342fb683ad2bbf930b21e69ffc1f17b42828fc75e9099e95fd3db22",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759244520,
      "headline": "Metsera Posts Promising Weight-Loss Drug Results. It Could Be a Win for Pfizer.",
      "id": 136937585,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pfizer said last week it would pay $47.50 per share for Metsera, and an extra $22.50 per share if its drugs hit certain milestones.",
      "url": "https://finnhub.io/api/news?id=042b8dcc6342fb683ad2bbf930b21e69ffc1f17b42828fc75e9099e95fd3db22"
    }
  },
  {
    "ts": null,
    "headline": "Can NVO Maintain Obesity Leadership With Next-Generation Candidates?",
    "summary": "Novo Nordisk is expanding beyond Wegovy and Ozempic with next-generation obesity candidates and strategic deals to defend its market lead.",
    "url": "https://finnhub.io/api/news?id=786579da3970d7316d2e88efb8f353df9fbe18a1941a0e6856535a04dddbe9cc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759243500,
      "headline": "Can NVO Maintain Obesity Leadership With Next-Generation Candidates?",
      "id": 136937586,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk is expanding beyond Wegovy and Ozempic with next-generation obesity candidates and strategic deals to defend its market lead.",
      "url": "https://finnhub.io/api/news?id=786579da3970d7316d2e88efb8f353df9fbe18a1941a0e6856535a04dddbe9cc"
    }
  },
  {
    "ts": null,
    "headline": "Is Lilly (LLY) a Buy as Wall Street Analysts Look Optimistic?",
    "summary": "The average brokerage recommendation (ABR) for Lilly (LLY) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
    "url": "https://finnhub.io/api/news?id=4ef033f156af398c2b08a04ff3a1ad95dbce2e1766c75dfb124cfff7ee5fc8a5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759239004,
      "headline": "Is Lilly (LLY) a Buy as Wall Street Analysts Look Optimistic?",
      "id": 136937587,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The average brokerage recommendation (ABR) for Lilly (LLY) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
      "url": "https://finnhub.io/api/news?id=4ef033f156af398c2b08a04ff3a1ad95dbce2e1766c75dfb124cfff7ee5fc8a5"
    }
  },
  {
    "ts": null,
    "headline": "Metsera strengthens case for Pfizer buyout with latest study data",
    "summary": "In a Phase 2 trial, a drug at the center of the $4.9 billion deal matched the type of weight loss trajectory seen in testing of Eli Lilly’s Zepbound.",
    "url": "https://finnhub.io/api/news?id=ff9f105ff73f927b7947c777bceb56731ead2ec56670541044a859b83e5d23e6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759233000,
      "headline": "Metsera strengthens case for Pfizer buyout with latest study data",
      "id": 136937588,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "In a Phase 2 trial, a drug at the center of the $4.9 billion deal matched the type of weight loss trajectory seen in testing of Eli Lilly’s Zepbound.",
      "url": "https://finnhub.io/api/news?id=ff9f105ff73f927b7947c777bceb56731ead2ec56670541044a859b83e5d23e6"
    }
  },
  {
    "ts": null,
    "headline": "Citigroup forecasts Big Tech's AI spending to cross $2.8 trillion by 2029",
    "summary": "(Reuters) -Citigroup has raised its forecast for AI-related infrastructure spending by tech giants to surpass $2.8 trillion through 2029, from $2.3 trillion estimated earlier, citing aggressive early investments by hyperscalers and growing enterprise appetite.  The AI boom ignited by ChatGPT's launch in late 2022 has continued to fuel staggering capital outlays and data center expansion despite a brief crisis of confidence sparked by China's cheaper DeepSeek model and lingering market concerns over U.S. President Donald Trump's tariff policies.  The Wall Street brokerage sees AI capex across hyperscalers to reach $490 billion by the end of 2026, up from its earlier estimate of $420 billion.",
    "url": "https://finnhub.io/api/news?id=e891d7851ac8af8433baac7f1aee0aa34064eb5c3ab435790696689d4b48c4e4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759231155,
      "headline": "Citigroup forecasts Big Tech's AI spending to cross $2.8 trillion by 2029",
      "id": 136936075,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Reuters) -Citigroup has raised its forecast for AI-related infrastructure spending by tech giants to surpass $2.8 trillion through 2029, from $2.3 trillion estimated earlier, citing aggressive early investments by hyperscalers and growing enterprise appetite.  The AI boom ignited by ChatGPT's launch in late 2022 has continued to fuel staggering capital outlays and data center expansion despite a brief crisis of confidence sparked by China's cheaper DeepSeek model and lingering market concerns over U.S. President Donald Trump's tariff policies.  The Wall Street brokerage sees AI capex across hyperscalers to reach $490 billion by the end of 2026, up from its earlier estimate of $420 billion.",
      "url": "https://finnhub.io/api/news?id=e891d7851ac8af8433baac7f1aee0aa34064eb5c3ab435790696689d4b48c4e4"
    }
  },
  {
    "ts": null,
    "headline": "The Truth About Novo Nordisk: 4 Myths That Don't Hold Up",
    "summary": "Novo Nordisk's Wegovy, especially at higher doses, rivals Eli Lilly's Zepbound in weight loss. Read why NVO stock is a Strong Buy.",
    "url": "https://finnhub.io/api/news?id=795b9cd9d1e7640b1da353077ec7b8908fc98c51423c93d0de012acdb4eda0b5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759224619,
      "headline": "The Truth About Novo Nordisk: 4 Myths That Don't Hold Up",
      "id": 136935891,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2198354842/image_2198354842.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk's Wegovy, especially at higher doses, rivals Eli Lilly's Zepbound in weight loss. Read why NVO stock is a Strong Buy.",
      "url": "https://finnhub.io/api/news?id=795b9cd9d1e7640b1da353077ec7b8908fc98c51423c93d0de012acdb4eda0b5"
    }
  },
  {
    "ts": null,
    "headline": "These 2 Top Dividend Stocks Are Finally Rebounding, and There Might Be More Upside Ahead",
    "summary": "It's hard to keep these longtime winners down for too long.",
    "url": "https://finnhub.io/api/news?id=ac14a3ddb5a2f4a8ce65c4eab1c1ec48cf7f6727d4d301b33068a3a0d2dc0080",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759220100,
      "headline": "These 2 Top Dividend Stocks Are Finally Rebounding, and There Might Be More Upside Ahead",
      "id": 136933887,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "It's hard to keep these longtime winners down for too long.",
      "url": "https://finnhub.io/api/news?id=ac14a3ddb5a2f4a8ce65c4eab1c1ec48cf7f6727d4d301b33068a3a0d2dc0080"
    }
  },
  {
    "ts": null,
    "headline": "Terns Pharmaceuticals: Valued As If It Can't Win",
    "summary": "Explore Terns Pharmaceuticals' obesity and oncology pipeline, strong cash position, and speculative HOLD rating.",
    "url": "https://finnhub.io/api/news?id=a574e7e6680682e8343a23007f4244d70bb896ad85a701fec882a5965a82444c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759215141,
      "headline": "Terns Pharmaceuticals: Valued As If It Can't Win",
      "id": 136935382,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2194223076/image_2194223076.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Explore Terns Pharmaceuticals' obesity and oncology pipeline, strong cash position, and speculative HOLD rating.",
      "url": "https://finnhub.io/api/news?id=a574e7e6680682e8343a23007f4244d70bb896ad85a701fec882a5965a82444c"
    }
  },
  {
    "ts": null,
    "headline": "Big Pharma’s retreat: Is NHS pricing behind investor pullbacks?",
    "summary": "Multinational pharmaceutical firms are pulling pack or pausing investments in the UK, blaming a lack of competitive drug pricing.View on euronews",
    "url": "https://finnhub.io/api/news?id=3364c0c8e93f31eda3774a6f0761852c9c6da22758f15db91170ab5c90068d65",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759211535,
      "headline": "Big Pharma’s retreat: Is NHS pricing behind investor pullbacks?",
      "id": 136934023,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Multinational pharmaceutical firms are pulling pack or pausing investments in the UK, blaming a lack of competitive drug pricing.View on euronews",
      "url": "https://finnhub.io/api/news?id=3364c0c8e93f31eda3774a6f0761852c9c6da22758f15db91170ab5c90068d65"
    }
  },
  {
    "ts": null,
    "headline": "3 Growth Stocks to Invest $1,000 Right Now",
    "summary": "Market leaders riding secular tailwinds are likely to be profitable long-term investments.",
    "url": "https://finnhub.io/api/news?id=2fb1909baec5fdbf1ce13f33e1a77ce7c655eb5ba97368622e29a463f3006ede",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759194360,
      "headline": "3 Growth Stocks to Invest $1,000 Right Now",
      "id": 136923768,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Market leaders riding secular tailwinds are likely to be profitable long-term investments.",
      "url": "https://finnhub.io/api/news?id=2fb1909baec5fdbf1ce13f33e1a77ce7c655eb5ba97368622e29a463f3006ede"
    }
  }
]